The Board of Directors of the company has appointed Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides.
Shaw replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.
A transformational year
The leadership changes follow a transformational year for Oncopeptides, when Pepaxti, was granted Marketing Authorization, in the European Union, the EEA-countries as well as in the UK. The company started the launch in Germany in October 2022 and has initiated market access activities regarding pricing and reimbursement. The appointment of a new CEO with extensive commercialization skills and experience, enables Oncopeptides to fully execute the commercialization and Medical Affairs activities of Pepaxti in Europe at this time, the company states.
“As we embark on this new phase of our journey as a commercial stage biotech company, dedicated to provide patient access to Pepaxti, I am very pleased to announce, that we have managed to attract Dr Monica Shaw as CEO of Oncopeptides AB (publ.),” says Per Wold-Olsen, Chairman of Oncopeptides. “I am also very grateful that Jakob Lindberg will continue his dedicated scientific engagement in Oncopeptides, in his capacity as Chief Scientific Officer.”
Dr Monica Shaw brings a wealth of executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to successful commercialization, globally and across many geographies, describes Oncopeptides. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, including Immunology, Oncology, Virology, Neurology and Rare Diseases.
“I am thrilled to join Oncopeptides and drive the commercialization of Pepaxti in Europe at this exciting time and become engaged in the development of the preclinical portfolio,” says Monica Shaw. “The recent full approvals of Pepaxti by the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency in the UK demonstrate that Pepaxti adds critically important clinical value to patients. I look forward to working with the team to ensure that patients with multiple myeloma, who continue to need new treatment options, can get access to and benefit from Pepaxti.”
Photo of Monica Shaw: Oncopeptides